An early advocate of indigenous reciprocity, the company seeks more funding to support FDA clinical trials.
Payton Nyquvest, Numinus’s CEO, sees the company’s move into the U.S. as a step towards “a global clinic network.”
Porta Sophia is building an online database of prior art pertaining to psychedelics with the goal of improving the flawed psychedelic patent process.
Partnerships between funders and researchers at Johns Hopkins illustrate how companies influence the direction of psychedelic science and the release of research data to the public domain.
Mimosa Therapeutics has created a cultured psilocybin mycelium product called Pearls that can be precisely dosed like synthetic psilocybin, but contains all the mushroom’s compounds.
Retreats, converted ketamine clinics, patient management software, professional associations and other service providers ramp up for Oregon’s psilocybin gold rush.
The NGO Blessings of the Forest is spearheading the new arrangement under the Nagoya Protocol, applying an international treaty to a psychedelic substance for the first time.
The psychedelic compound in toad venom is being used to develop therapies for everything from cluster headaches to chronic depression.
The innovation may be the ethical alternative to the controversial practice of collecting Bufo toad venom.
In an exclusive interview, Doblin discusses MAPS’s goal to raise $150 over the next three years, and their $70 million investment fund with Vine Ventures to help meet that funding goal.